Durable complete remissions in HIV-associated hodgkin lymphoma after treatment with only one cycle of chemotherapy complicated by Sepsis

Clinical Lymphoma and Myeloma

Volumn 9, Issue 3, 2009, Pages 247-249

  Martin, Peter ^a   Leonard, John ^a   Coleman, Morton ^a   Furman, Richard ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

AIDS; Hodgkin's lymphoma; Immunosuppression; Immunotherapy

Indexed keywords

ABACAVIR; ALBUMIN; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; HEMOGLOBIN; HYPERTENSIVE AGENT; LAMIVUDINE; LOPINAVIR; NELFINAVIR; PREDNISONE; PROCARBAZINE; RITONAVIR; STAVUDINE; STEROID; TENOFOVIR; VINBLASTINE; VINCRISTINE; IMMUNOSUPPRESSIVE AGENT;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; B CELL LYMPHOMA; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CASE REPORT; CD4 LYMPHOCYTE COUNT; CERVICAL LYMPHADENOPATHY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; HEMOGLOBIN BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; HYPOTENSION; IMMUNOREACTIVITY; LARGE CELL LYMPHOMA; LEUKOCYTE COUNT; LUNG VENTILATION; LYMPHOCYTE COUNT; MALE; MIXED CELLULARITY HODGKIN LYMPHOMA; MULTIPLE CYCLE TREATMENT; NODULAR SCLEROSIS HODGKIN LYMPHOMA; PATHOPHYSIOLOGY; PNEUMOCYSTIS PNEUMONIA; REMISSION; RESPIRATORY DISTRESS; RESPIRATORY FAILURE; SEPSIS; STREPTOCOCCUS MITIS; TREATMENT RESPONSE; VIRUS LOAD; IMMUNOTHERAPY; METHODOLOGY; MIDDLE AGED; TREATMENT OUTCOME; VIROLOGY;

ADULT; ANTINEOPLASTIC AGENTS; HIV INFECTIONS; HODGKIN DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; LYMPHOMA, AIDS-RELATED; MALE; MIDDLE AGED; REMISSION INDUCTION; SEPSIS; TREATMENT OUTCOME;

EID: 69149091532     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2009.n.049     Document Type: Article

References (22)

1. Kirk O, Pedersen C, Cozzi-Lepri A, et al. Non-Hodgkin lymphoma in HIVinfected patients in the era of highly active antiretroviral therapy. Blood 2001; 98:3406-12.
2. Biggar RJ, Jaffe ES, Goedert JJ, et al. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood 2006; 108:3786-91.
3. Stein H, Mann R, Delsol G. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001.
4. Glaser SL, Clarke CA, Gulley ML, et al. Population-based patterns of human immunodeficiency virus-related Hodgkin lymphoma in the Greater San Francisco Bay Area, 1988-1998. Cancer 2003; 98:300-9.
5. Hasenclever D, Diehl V, Armitage JO, et al. A Prognostic Score for Advanced Hodgkin's Disease. N Engl J Med 1998; 339:1506-14.
6. The International Chl VPPTG. ChlVPP therapy for Hodgkin's disease: Experience of 960 patients. Ann Oncol 1995; 6:167-72.
7. Parekh S, Koduri PR. Spontaneous regression of HIV-associated Hodgkin's disease. Am J Hematol 2003; 72:153-4.
8. Mangel J, Barth D, Maceachren J, et al. Spontaneous regression of Hodgkin's Disease: Two case reports and a review of the literature. Hematology 2003; 8:191-6.
9. Bang SM, Cheong JW, Yang WI, et al. An unusual case of remission of Hodgkin's Disease after a single course of COPP-ABV chemotherapy followed by infectious complications. Yonsei Med J 2005; 46:425-30.
10. Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2005; 23:4634-42.
11. Spina M, Gabarre J, Rossi G, et al. Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. Blood 2002; 100:1984-8.
12. Hobohm U. Fever and cancer in perspective. Cancer Immunol Immunother 2001; 50:391-6.
13. Wooldridge JE, Ballas Z, Krieg AM, et al. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood 1997; 89:2994-8.
14. Klinman DM. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol 2004; 4:249-59.
15. Friedberg JW, Kim H, McCauley M, et al. Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. Blood 2005; 105:489-95.
16. Leonard JP, Link BK, Emmanouilides C, et al. Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma. Clin Cancer Res 2007; 13:6168-74.
17. Bucy RP, Hockett RD, Derdeyn CA, et al. Initial increase in blood CD4+ lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J Clin Invest 1999; 103:1391-8.
18. Pakker NG, Notermans DW, de Boer RJ, et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med 1998; 4:208-14.
19. Paya CV, Fung JJ, Nalesnik MA, et al. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 1999; 68:1517-25.
20. Ferguson NR, Galley HF, Webster NR. T helper cell subset ratios in patients with severe sepsis. Intensive Care Med 1999; 25:106-9.
21. Hotchkiss RS, Osmon SB, Chang KC, et al. Accelerated lymphocyte death in sepsis occurs by both the death receptor and mitochondrial pathways. J Immunol 2005; 174:5110-8.
22. Younes A, Romaguera J, Hagemeister F, et al. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer 2003; 98:310-4.